Christi Shaw, Kite CEO (Jeff Rumans)

Gilead and Kite nab an­oth­er ap­proval for Tecar­tus, as lead­ing CAR-T port­fo­lio con­tin­ues to grow

Gilead and Kite took an­oth­er step Fri­day to­ward ex­pand­ing their fran­chise of CAR-T drugs, nab­bing a new ap­proval for Tecar­tus.

The FDA OK’ed the ther­a­py for adults with re­lapsed or re­frac­to­ry B-cell pre­cur­sor acute lym­phoblas­tic leukemia, Gilead an­nounced Fri­day. It’s the drug’s sec­ond in­di­ca­tion af­ter Gilead ini­tial­ly launched the CAR-T in 2020 for adults with re­lapsed or re­frac­to­ry man­tle cell lym­phoma.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.